I vividly recollect asking my physics professor for a letter of recommendation. I sat in the front row of his lectures and visited his office hours most weeks in the semester. He turned me down because he was “too busy.” I was devastated—and panicked about asking my next choice for letter writer. On the plus…
Anti-P. copri Antibody Responses in Patients with RA
Background & Objectives Rheumatoid arthritis (RA) is a chronic autoimmune disease associated with immune responses to the patient’s own antigens and characterized by inflammation and substantial joint destruction. Prevotella copri, a gut commensal bacterium, has been reported to be an immune-relevant organism in individuals with RA. This study sought to evaluate antibody responses to anti-P….
Diet May Help Reduce Inflammation in RA
In a small study, an anti-inflammatory diet helped reduce pain and swelling in a subset of people with rheumatoid arthritis (RA). Diet changes are complementary to standard treatment. Diet-related research can be challenging, but many patients with RA are motivated to try healthy changes.
A Unique Partnership Gives the ACR a Voice in Insurance Legislation Development
A recent meeting of the National Council of Insurance Legislators (NCOIL) featured discussions of many topics important to ACR members, including pharmacy benefit manager legislation, biomarker testing and transparency in the healthcare market.
The ACR Recommends Inflation-Based Medicare Payment Updates
In a letter to Congress, the ACR, AMA and other groups urge legislation that would provide annual inflation-based Medicare payment updates based on the full Medicare Economic Index.
COVID-19 EUA Testing Requirement Change
On Feb. 3, the U.S. Food & Drug Administration (FDA) revised its Letters of Authorization for two emergency use authorizations (EUAs), Paxlovid and Lagevrio, to remove the requirement for positive test results to prescribe these drugs. The agency continues to recommend that providers use direct SARS-CoV-2 viral testing to help diagnose COVID-19. The FDA recognizes…
What We Know about COVID-19 in 2023: Variants, Vaccines, New Therapies & More
Although a less central focus than it was three years ago, rheumatologists must still consider the prevention and management of SARS-CoV-2 in their patients. The following update shares ongoing considerations related to the COVID-19 pandemic. Outcomes At the beginning of the pandemic, it was unclear whether patients with rheumatic disease would be at higher risk…
Long COVID: Experts Weigh in on Increasingly Common Syndrome
A minority of patients experience lingering symptoms after infection with SARS-CoV-2, similar to some other previously known post-infection syndromes. Although we are just beginning to understand the different presentations, pathophysiology, risk factors, prognosis and treatment of long COVID, rheumatologists can play a leadership role in managing patients with the illness and contributing to this important research…
FDA Approves Sarilumab for the Treatment of Adults with Glucocorticoid-Resistant PMR
Sarilumab is now FDA approved to treat adults with polymyalgia rheumatica who have had an inadequate response to glucocorticoids or who cannot tolerate a glucocorticoid taper. This new indication is based on results from the multicenter, phase 3 SAPHYR trial.
Is Exercise-Based Physical Therapy Effective for Degenerative Meniscal Tears?
Research has demonstrated that exercise-based physical therapy is as effective at maintaining knee function as surgery in patients with degenerative meniscal tears at risk of developing knee osteoarthritis.
- « Previous Page
- 1
- …
- 56
- 57
- 58
- 59
- 60
- …
- 798
- Next Page »